trending Market Intelligence /marketintelligence/en/news-insights/trending/twp4uqx64lsx1m_rpocwma2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Heron Therapeutics plans common stock offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Heron Therapeutics plans common stock offering

Heron Therapeutics Inc. said it is planning to undertake an underwritten registered public offering of its common stock.

The San Diego-based biotechnology company said it intends to use the net proceeds for the commercial launch of HTX-011, if approved by the U.S. Food and Drug Administration, and further clinical studies of HTX-011, which is under investigation to reduce post-surgery pain.

Heron also plans to use the net proceeds for the continued commercialization of medicines - Cinvanti and Sustol, used to prevent acute and delayed chemotherapy-induced nausea and vomiting; for future clinical trials, other product development activities and general corporate purposes.

The company intends to grant the underwriters an option to buy up to an additional 15% of the shares sold in the offering.

Jefferies, Cowen and Evercore ISI are acting as joint book-running managers, while Cantor and JMP Securities are acting as lead managers for the offering. LifeSci Capital, Lake Street Capital Markets, National Securities Corp., Noble Capital Markets and Northland Capital Markets are each acting as co-managers for the offering.